These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38264841)

  • 1. The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
    Sica M; Notaro R
    Am J Hematol; 2024 Mar; 99(3):505-507. PubMed ID: 38264841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
    Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
    Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
    Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
    Front Immunol; 2020; 11():1460. PubMed ID: 32793201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    Logue GL; Rosse WF; Adams JP
    J Clin Invest; 1973 May; 52(5):1129-37. PubMed ID: 4700488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells.
    Logue GL
    Blood; 1977 Aug; 50(2):239-47. PubMed ID: 17439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.
    Mastellos DC; Ricklin D; Yancopoulou D; Risitano A; Lambris JD
    Expert Rev Hematol; 2014 Oct; 7(5):583-98. PubMed ID: 25213458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Mastellos DC; Reis ES; Yancopoulou D; Risitano AM; Lambris JD
    Semin Hematol; 2018 Jul; 55(3):167-175. PubMed ID: 30032754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
    Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
    Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
    Risitano AM; Frieri C; Urciuoli E; Marano L
    Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.